4 completed, 2 terminated. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow Ahmad Tarhini: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study High dose bolus interleukin-2 (HD IL2) - Melanoma | Phase 2 | Terminated | Ahmad Tarhini | 1 | 2016-09-01 | 2018-04-20 |
| AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer AMG 102 and erlotinib - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Completed | Ahmad Tarhini | 49 | 2011-08-01 | 2017-06-22 |
| Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer LBH589 and carboplatin with etoposide - Small Cell Lung Cancer | Phase 1 | Terminated | Ahmad Tarhini | 7 | 2009-09-01 | 2017-06-22 |
| Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Peptide vaccine, GM-CSF, PF3512676 - Intraocular Melanoma, Malignant Conjunctival Neoplasm | Phase 1 | Completed | Ahmad Tarhini | 22 | 2008-10-01 | 2017-06-22 |
| Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma Anti-CTLA4 monoclonal antibody and HDI - Melanoma | Phase 2 | Completed | Ahmad Tarhini | 37 | 2006-11-01 | 2017-06-22 |
| Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung Cancer RAD001 (everolimus) - Small Cell Lung Cancer | Phase 2 | Completed | Ahmad Tarhini | 40 | 2006-10-01 | 2017-10-19 |
Melanoma (3) · Small Cell Lung Carcinoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Recurrence (1) · Uveal Melanoma (1)
Carboplatin (1) · Erlotinib Hydrochloride (1) · Etoposide (1) · Everolimus (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Panobinostat (1) · Podophyllotoxin (1) · ProMune (1) · Protein Subunit Vaccines (1) · rilotumumab (1) · sargramostim (1) · tremelimumab (1)
United States (6)
Ahmad A Tarhini, MD (1) · Ahmad A. Tarhini, MD, MS (1)